John Crowley (File photo)
Amicus shares slammed as lead PhIII drug fails a key head-to-head test for Pompe disease — but the CEO still projects an FDA OK and bright future
Amicus stock got hammered Thursday afternoon after the biotech put out word that the crown jewel in the pipeline just failed the primary endpoint in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
